Boston Scientific Corporation

BSX

$47.66

+1.50%

2026-09-04 12:39:00 EDT+$0.71

Healthcare

Medical - Devices

NYSE

Active Trading

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical ...

Price Action of BSX

$47.66

+1.50%+$0.71

High—

Low—

52W High-56.5%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Boston Scientific Corporation is a global leader in medical technology, with a mission to transform lives through innovative medical solutions. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and operates in over 127 countries. As of the latest data, Boston Scientific has ...Boston Scientific Corporation is a global leader in medical technology, with a mission to transform lives through innovative medical solutions. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and operates in over 127 countries. As of the latest data, Boston Scientific has approximately 59,000 employees and generates annual net sales exceeding $20 billion, with a market capitalization of about $73 billion. The company is organized into three business segments: MedSurg, Rhythm and Neuro, and Cardiovascular. MedSurg focuses on gastrointestinal, pulmonary, urological, and pelvic health solutions, including stents, catheters, and minimally invasive surgical tools. Rhythm and Neuro offers implantable devices for cardiac rhythm management, such as pacemakers, defibrillators, and cardiac resynchronization therapy, as well as neuromodulation systems for chronic pain and movement disorders. Cardiovascular includes interventional cardiology products like drug-eluting stents, intravascular imaging catheters, and structural heart therapies, along with peripheral interventions for arterial and venous diseases. The company also provides cancer treatment solutions, including embolization devices and ablation systems. Boston Scientific has a strong commitment to research and development, investing approximately $2 billion annually, which represents about 10% of revenue. This investment has led to a robust pipeline of innovative products. Financially, the company demonstrates solid profitability metrics: gross profit margin of 71.2%, operating profit margin of 21.5%, and net profit margin of 17.5%. Its return on equity stands at 14.9%, and its debt-to-equity ratio is a conservative 0.506, indicating a balanced capital structure. The company's cash flow is strong, with an operating cash flow of $3.065 per share and free cash flow of $2.453 per share. In terms of valuation, BSX trades at a price-to-earnings ratio of approximately 19.9 and a price-to-sales ratio of 3.5, reflecting its growth prospects in the medical device industry. Key leaders include CEO Michael F. Mahoney, who has served since 2009 and also serves as Chairman. The company was publicly listed on the NYSE in 1992 and has a history of strategic acquisitions to drive growth. Boston Scientific's culture emphasizes patient-centric innovation, with a vision to advance science for life, helping patients experience more of what truly matters.ExpandCollapse

Founded

1979

Employees

59000

CEO

Michael F. Mahoney

Full Name

Boston Scientific Corporation

Sector

Healthcare

Industry

Medical - Devices

ROE

14.90%

Market Cap

$69.06B

Current Ratio

1.24

WACC

6.66%

ROIC

13.36%

Contact Information

https://www.bostonscientific.com

508 683 4000

300 Boston Scientific Way, Marlborough, MA 01752-1234

Key Metrics of BSX

Snapshot

Latest / TTM · 6 periods

Market Cap

$69.06B

ROCE

11.6%

EV / EBITDA

14.49x

+1.2% YoY

FCF Yield

5.2%

+2.6% YoY

Cash Conversion Cycle

173.8d

Current Ratio

1.24

Quick take

TTM —

Positive CCC

Financial Highlights of BSX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

71.2%

Net Margin

17.5%

P/E Ratio

19.05x

n/a

Debt / Equity

0.51

n/a

Current Ratio

1.24

Dividend Yield

0.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of BSX

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.81 · Revenue $5.26B · 15 analysts
Oct 28, 2026In 54 days
Q3 FY2026 · Earnings report
Est. EPS $0.80
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.84 · Revenue $5.44B · 14 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $3.30 · Revenue $21.35B · 15 analysts

Recent history

Aug 3, 2026
Q2 FY2026 · Results reported
EPS $0.61 · Revenue $5.44B
View filing
May 1, 2026
Q1 FY2026 · Results reported
EPS $0.90 · Revenue $5.20B
View filing
Feb 17, 2026
FY2025 · Annual results
EPS $1.94 · Revenue $20.07B
View filing
Nov 3, 2025
Q3 FY2025 · Results reported
EPS $0.50 · Revenue $5.07B
View filing
Aug 1, 2025
Q2 FY2025 · Results reported
EPS $0.53 · Revenue $5.06B
View filing
Mar 31, 2025
Q1 FY2025 · Results reported
EPS $0.45 · Revenue $4.66B

Financial Statements of BSX

Next Earnings Date

Oct 28, 2026

EPS Est. 0.8 · Fiscal period ending 2026-09-30

D-54

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$20.1B	+19.9%	+4.6%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$2.9B	+55.7%	-32.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+69.0%	+12.6%	+1.8%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+19.8%	+25.7%	+5.1%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+14.4%	+29.9%	-35.1%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$3.7B	+38.3%	+648.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+18.2%	+15.4%	+615.1%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	51.2%	+0.1%	+18.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.62x	+49.5%	-34.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$43.7B	+10.9%	+2.0%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	1.94 vs 3.04	-36.1%	0.61 vs 0.81	-24.4%
Revenue Surprise	$20.1B vs $20.1B	+0.0%	$5.4B vs $5.3B	+3.5%

Insider Transactions of BSX

Acquisitions (A)

Since Jul 31, 2026

Disposals (D)

Since Jul 31, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 25, 2026	Morano Susan E	director	Common Stock	A	2,040	$49.22
Aug 11, 2026	Woodworth Emily	officer: SVP, Global Controller and CAO	Common Stock	A	2,930	$51.19
Aug 10, 2026	Monson Jonathan	officer: EVP and CFO	Common Stock	A	9,908	$50.46
Aug 5, 2026	Habiger David C	director	Common Stock	A	2,100	$47.59
Aug 4, 2026	Habiger David C	director	Common Stock	A	140	$48.59

Earnings Call Transcript of BSX

1 transcript segments

Q2 2026

Unknown Speaker

Operator : Good morning, and welcome to the Boston Scientific Second Quarter 2026 Earnings Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead. Lauren Tengler : Thank you, Drew, and thanks to everyone for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Jon Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and Jon will be joined by our Chief Medical Officer, Dr. Ken Stein. We issued a press release earlier this morning announcing our Q2 2026 results, which included reconciliations of the non-GAAP measures used in this release. The release as well as the reconciliations of non-GAAP measures used in today's call can be found on the Investor Relations section of our website. Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations, and organic revenue further excludes certain acquisitions and divestitures for which there is less than a full period of comparable net sales. Guidance excludes the previously announced agreement to acquire Penumbra, which is expected to close in the second half of 2026, subject to customary closing conditions. For more information, please refer to the Q2 financial and operating highlights deck, which may be found on the Investor Relations section of our website. On this call, all references to sales and revenue are organic and relative growth as compared to the same quarter of prior year, unless otherwise specified. This call contains forward-looking statements regarding, among other things, our financial performance, business plans, market expectations, and product performance and development. These statements are based on our current beliefs using information available to us as of today's date and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect or certain risks or uncertainties materialize, actual results could vary materially from those projected by forward-looking statements. Factors that may cause such differences are discussed in our periodic reports and other filings with the SEC, including the Risk Factors section of our most recent annual report on Form 10-K. Boston Scientific disclaims any intention or obligation to update these forward-looking statements, except as required by law. In addition, this call does not constitute an offer to sell or the solicitation of any offer to buy any securities or solicitation of any vote or approval in connection with the proposed transaction with Penumbra. Boston Scientific has filed the SEC registration statement on Form S-4 containing a proxy statement of Penumbra and a prospectus of Boston Scientific that contains important information about Penumbra, Boston Scientific, the proposed transaction and related matters. At this point, …

Leadership Team of BSX

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Michael F. Mahoney	Chairman, President & Chief Executive Officer	USD 5,732,403	Male	1965	Active
Joseph Fitzgerald	Executive VP & Group President of Cardiovascular	USD 2,396,262	Male	1964	Active
Arthur Crosswell Butcher	Executive Vice President and Group President of MedSurg & Asia Pacific	USD 1,976,990	Male	1971	Active
Vance R. Brown	EVP, General Counsel & Corporate Secretary	USD 1,602,123	Male	1970	Active
Jonathan Monson	Executive Vice President & Chief Financial Officer	USD 1,470,301	Male	1974	Active
Adam Smith	General Manager of Global Sales & Marketing	—	Male	—	Active
Paudie O'Connor	Executive Vice President of Global Operations	—	Male	1968	Active
Brenda Becker	Senior Vice President of Global Government Affairs	—	Female	1960	Active
Emily Woodworth	Senior Vice President, Global Controller & Chief Accounting Officer	—	Female	1978	Active
Miriam O'sullivan	Senior Vice President & Chief Human Resources Officer	—	Female	1981	Active

Recent News of BSX

Zacks Investment Research8/28/2026Neutral

Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research8/28/2026Neutral

New Strong Sell Stocks for August 28th

AU, APTV and BSX have been added to the Zacks Rank #5 (Strong Sell) List on August 28th, 2026.

The Motley Fool8/26/2026Neutral

Stock Market Today, Aug. 26: Boston Scientific Shares Fall 5% on Cybersecurity Incident and Product Recall

On Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.

Investopedia8/26/2026Neutral

Boston Scientific Stock Slides After Cyberattack Caused ‘Global Disruption'

Boston Scientific's stock is sliding in the wake of a major cyberattack, adding to its recent woes.

TechCrunch8/26/2026Neutral

Medical device maker Boston Scientific says a cyberattack is causing a ‘global disruption' to its operations

A cyberattack on U.S. medical device maker Boston Scientific is causing an ongoing “global disruption” to its operations, according to a federal regulatory filing on Wednesday, the latest healthtech giant to face a cyberattack in recent weeks.

Historical Employee Count of BSX

Current

59,000

Change

+11.32%

Minimum

41,000

Maximum

59,000

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	59,000	10-K	Feb 17, 2026	View
Dec 31, 2024	53,000	10-K	Feb 18, 2025	View
Dec 31, 2023	48,000	10-K	Feb 20, 2024	View
Dec 31, 2022	45,000	10-K	Feb 23, 2023	View
Dec 31, 2021	41,000	10-K	Feb 23, 2022	View

Related stocksMedical - Devices

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Boston Scientific Corporation